Pharmacological inhibition of fatty acid transporter protein 2 (FATP2) using lipofermata abrogates the activity of polymorphonuclear MDSC and substantially inhibits tumor progression in a mouse model of pancreatic and colorectal cancers.184. Here, SLC27A2 is linked to neoplasm.